186 related articles for article (PubMed ID: 14612147)
1. Dynamic regulation of the dopamine transporter.
Mortensen OV; Amara SG
Eur J Pharmacol; 2003 Oct; 479(1-3):159-70. PubMed ID: 14612147
[TBL] [Abstract][Full Text] [Related]
2. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands.
Gulley JM; Zahniser NR
Eur J Pharmacol; 2003 Oct; 479(1-3):139-52. PubMed ID: 14612145
[TBL] [Abstract][Full Text] [Related]
3. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine.
Kahlig KM; Galli A
Eur J Pharmacol; 2003 Oct; 479(1-3):153-8. PubMed ID: 14612146
[TBL] [Abstract][Full Text] [Related]
4. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
5. Interactions of cations and anions with the binding of uptake blockers to the dopamine transporter.
Bonnet JJ
Eur J Pharmacol; 2003 Oct; 479(1-3):199-212. PubMed ID: 14612150
[TBL] [Abstract][Full Text] [Related]
6. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice.
Huotari M; Santha M; Lucas LR; Karayiorgou M; Gogos JA; Männistö PT
J Pharmacol Exp Ther; 2002 Dec; 303(3):1309-16. PubMed ID: 12438556
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter as target for drug development of cocaine dependence medications.
Dutta AK; Zhang S; Kolhatkar R; Reith ME
Eur J Pharmacol; 2003 Oct; 479(1-3):93-106. PubMed ID: 14612141
[TBL] [Abstract][Full Text] [Related]
8. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
Rothman RB; Dersch CM; Carroll FI; Ananthan S
Synapse; 2002 Mar; 43(4):268-74. PubMed ID: 11835522
[TBL] [Abstract][Full Text] [Related]
9. Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors.
Madras BK; Fahey MA; Miller GM; De La Garza R; Goulet M; Spealman RD; Meltzer PC; George SR; O'Dowd BF; Bonab AA; Livni E; Fischman AJ
Eur J Pharmacol; 2003 Oct; 479(1-3):41-51. PubMed ID: 14612136
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines.
Ananthan S; Saini SK; Khare R; Clayton SD; Dersch CM; Rothman RB
Bioorg Med Chem Lett; 2002 Aug; 12(16):2225-8. PubMed ID: 12127543
[TBL] [Abstract][Full Text] [Related]
11. Locomotor activity induced by noncompetitive NMDA receptor antagonists versus dopamine transporter inhibitors: opposite strain differences in inbred long-sleep and short-sleep mice.
Hanania T; Zahniser NR
Alcohol Clin Exp Res; 2002 Apr; 26(4):431-40. PubMed ID: 11981117
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter.
Pristupa ZB; McConkey F; Liu F; Man HY; Lee FJ; Wang YT; Niznik HB
Synapse; 1998 Sep; 30(1):79-87. PubMed ID: 9704884
[TBL] [Abstract][Full Text] [Related]
13. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
[TBL] [Abstract][Full Text] [Related]
14. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging.
Lindsey KP; Wilcox KM; Votaw JR; Goodman MM; Plisson C; Carroll FI; Rice KC; Howell LL
J Pharmacol Exp Ther; 2004 Jun; 309(3):959-69. PubMed ID: 14982963
[TBL] [Abstract][Full Text] [Related]
15. Rapid regulation of the dopamine transporter: role in stimulant addiction?
Zahniser NR; Sorkin A
Neuropharmacology; 2004; 47 Suppl 1():80-91. PubMed ID: 15464127
[TBL] [Abstract][Full Text] [Related]
16. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
Wersinger C; Prou D; Vernier P; Sidhu A
FASEB J; 2003 Nov; 17(14):2151-3. PubMed ID: 12958153
[TBL] [Abstract][Full Text] [Related]
17. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
[TBL] [Abstract][Full Text] [Related]
18. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys.
Ginsburg BC; Kimmel HL; Carroll FI; Goodman MM; Howell LL
Pharmacol Biochem Behav; 2005 Mar; 80(3):481-91. PubMed ID: 15740791
[TBL] [Abstract][Full Text] [Related]
19. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter.
Li LB; Chen N; Ramamoorthy S; Chi L; Cui XN; Wang LC; Reith ME
J Biol Chem; 2004 May; 279(20):21012-20. PubMed ID: 15024013
[TBL] [Abstract][Full Text] [Related]
20. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Paris I; Martinez-Alvarado P; Perez-Pastene C; Vieira MN; Olea-Azar C; Raisman-Vozari R; Cardenas S; Graumann R; Caviedes P; Segura-Aguilar J
J Neurochem; 2005 Mar; 92(5):1021-32. PubMed ID: 15715653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
